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Abstract The objective of this study is to estimate the
prevalence of gastroesophageal reflux disease (GERD) and
heartburn in migraine patients and examine their use of
non-steroidal anti-inflammatory drugs (NSAIDs) or aspi-
rin-containing medications when treating acute migraine
attacks. Responses from a web-based survey of migraine
patients were matched to the same patient’s responses on a
general health survey. A total of 1,832 migraineurs (92.0%)
were successfully matched. A total of 403 migraineurs
(22.0%) reported having diagnosed GERD, 212 (11.6%)
reported diagnosed heartburn, and 290 (15.8%) reported
reflux symptoms but were undiagnosed. The most common
prescription drugs used to treat migraines were triptans.
First-line NSAID/aspirin medication use was 10.0% among
diagnosed GERD and heartburn patients, 17.8% among
undiagnosed patients, and 11.8% among GERD/heartburn-
free migraineurs. In conclusion, almost half of migraineurs
reported physician-diagnosed GERD and heartburn or
symptoms of these conditions. Use of NSAID medications
for migraine is fairly common among diagnosed GERD
patients and more so for those with undiagnosed GERD
symptoms. Physicians should minimize prescribing NSA-
IDs or NSAID-containing acute migraine medications in
this population.
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Introduction
Migraine, which currently affects 17 and 5.6% of women
and men, respectively, in the US, is highly prevalent within
the general population [1]. While migraine headache has a
substantial impact on both the individual and society, it
remains under-diagnosed and under-treated [1–3]. Accu-
rate assessment of the clinical presentation of migraine and
its co-prevalent conditions can help to guide physicians to
maximize the therapeutic benefit of migraine treatment
while minimizing untoward side effects.
Prior research has documented associations between
migraine and a number of other conditions at greater
prevalence than might be expected. Common comorbidities
of migraine include anxiety, depression, epilepsy, insom-
nia, obesity, cardiovascular disease and stroke [4–7].
Migraine has also been linked to several gastrointestinal
disorders including colitis, irritable bowel syndrome and
peptic ulcer disease [8–10]. Research examining the co-
prevalence of headaches and common gastrointestinal
disorders such as gastroesophageal reflux disease (GERD)
and heartburn is scarce, although available studies have
supported an increased prevalence of these conditions
among migraineurs [10, 11]. While the comorbidity of
GERD and migraine is not known, a population-based
study found that GERD affects between 13.2 and 20% of
the US population [12].
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The presence of gastroesophageal reflux disorder among
migraineurs may present a unique treatment challenge for
clinicians as several commonly used acute migraine med-
ications, including non-steroidal anti-inflammatory drugs
(NSAIDs) and aspirin, are known to cause gastrointestinal
toxicity and exacerbation of erosive esophageal conditions
[13]. NSAIDs and aspirin-containing medications (collec-
tively referred to as NSAIDs) are commonly used by
patients as either stand-alone acute migraine treatment or
as part of a combination regimen (co-administered with
another anti-migraine medication or as a rescue medication
when first-line medication fails) [14]. Furthermore, pre-
scription of NSAID use has been found to nearly double
the risk of developing GERD in a controlled analysis of
Medicaid users [15]. Undetected GERD among migrai-
neurs may lead to the injudicious use of NSAIDs for
headache and other pain, which may aggravate their
underlying condition and increase healthcare resource uti-
lization on the part of this population [13, 16]. This study
aims to assess the one-time prevalence of self-reported
diagnosed GERD and heartburn symptoms from a popu-
lation-based sample of migraineurs, and to examine acute
migraine medication use by migraine patients with these
conditions, particularly the prescription and over-the-
counter (OTC) use of NSAIDs and aspirin.
Methods
Study population and data collection
A cross-sectional, web-based migraine survey was admin-
istered between November 2006 and January 2007.
Participants must have previously reported physician-
diagnosed migraine on the 2006 National Health and
Wellness Survey (NHWS), a nationwide survey of con-
sumer healthcare attitudes, opinions, and self-reported
diseases and conditions. The NHWS employs quota sam-
pling based on age and race, and invitations are sent to the
representative men and women within each quota for a
total sample of 7,000 respondents per month. Inclusionary
criteria were United States residency, 18 years of age or
older, the ability to read and write English, agreement
(consent) to study participation and not having participated
in the survey during a previous month in 2006. Participants
were excluded if any of the above criteria was not met.
After consenting, study participants were instructed to
complete the migraine survey within 24 h of resolution of
their next migraine attack, if such an attack occurred within
7 days of receipt of the study invitation. Migraine survey
questions solicited demographic information, migraine
history and treatment, presence of migraine-associated
symptoms and current headache frequency and severity
from participants. Information on GERD and heartburn
conditions was retrieved by matching individual participant
responses to the full NHWS dataset through unique iden-
tification numbers. The survey received central IRB
approval (Essex IRB, Lebanon, NJ) and was fully com-
pliant with all applicable state and federal privacy laws as
well as the Health Insurance Portability and Accountability
Act (HIPAA).
Measures
GERD and heartburn diagnosis
The prevalence of GERD or heartburn was ascertained by
the NHWS question ‘‘Which of the following conditions
have you experienced in the past 12 months?’’ This was
followed by a checklist of diseases and conditions includ-
ing GERD and, separately, heartburn. If GERD was
reported, the follow-up question ‘‘Has your GERD been
diagnosed by a physician?’’ was asked. Similarly, if
heartburn was reported, participants were asked ‘‘Has your
heartburn ever been diagnosed by a physician?’’ Patients
who reported being diagnosed with both GERD and
heartburn were classified as having diagnosed GERD.
Migraineurs were classified into four mutually exclusive
sub-populations: (1) those with physician-diagnosed
GERD, (2) physician-diagnosed heartburn only (but not
GERD), (3) undiagnosed symptoms of GERD or heartburn
(symptomatic GERD/heartburn) and (4) migraineurs
without GERD or heartburn symptoms (i.e., GERD/heart-
burn-free).
Medication use
Acute migraine medication use for participants’ most
recent attack was ascertained by the question ‘‘What first
migraine medication did you take?’’ Responses were
classified into one of eight categories: triptans, prescription
NSAIDs or NSAID-containing combinations, prescription
aspirin-containing combinations, opioids and opioid-con-
taining combinations, other prescription medications, OTC
NSAIDs, OTC aspirin and aspirin-containing combinations
and other OTC medications. For the purposes of this study,
a combination medication containing both an opioid and an
NSAID or an opioid and aspirin were classified as an
NSAID-containing combination and an aspirin-containing
combination, respectively.
Data analysis
A secondary data analysis of the matched dataset was
conducted. Demographic and migraine characteristics for
each of the migraine sub-populations were compared using
36 J Headache Pain (2009) 10:35–43
123
Chi-square statistics for categorical variables, and where
appropriate, Fisher’s exact tests. For categorical variables,
individual P values were adjusted in a step-up fashion
using Benjamin–Hochberg’s method to correct for multiple
comparisons [17]. Continuous variables were analyzed by
comparing adjusted group means using analysis of variance
(ANOVA) for non-normal distributions. Post-hoc analyses
for differences between group means were identified with
Scheffe’s multiple comparisons procedure. P values less
than or equal to 0.05 were considered statistically signifi-
cant, and only P values less than 0.10 were reported in
results. Percentages were rounded to the nearest tenth when
presented. All analyses were generated with SAS Statistical
Analysis Software, Version 9.1
Results
A total of 4,000 potential eligible migraineurs were con-
tacted. Of them, 2001 completed the online migraine attack
survey (50.0%). A total of 1,832 migraineurs (92.0%) were
matched to their responses on the 2006 NHWS survey, thus
providing data on potential health-related comorbidities.
The resulting classification of the four mutually exclusive
migraine sub-populations derived from the total sample is
presented in Fig. 1.
Of 1,832 matched migraine patients (mean age
41.1 years; 73% female), 403 (22.0%) reported physician-
diagnosed GERD, 212 (11.6%) reported physician-diag-
nosed heartburn, and an additional 290 (15.8%) reported
having symptoms of GERD and/or heartburn but were not
diagnosed. Of the 403 respondents diagnosed with GERD,
78% (n = 291) reported having heartburn symptoms, and
the majority (68%, n = 274) also reported being diagnosed
with heartburn. In total, 905 (49.4%) reported either
diagnosed or symptomatic GERD and/or heartburn
(Fig. 1).
Sample characteristics of the study participants are
presented in Table 1. Several differences were observed
among the migraine sub-populations. Migraineurs with
physician-diagnosed GERD were older (P = 0.05) and
more likely male (P = 0.02) than either migraineurs with
undiagnosed GERD or heartburn symptoms or those who
were GERD/heartburn free. Those with diagnosed GERD
were also more likely to suffer from severe migraines
(P = 0.03) and chronic daily headaches (P \ 0.01) than
either migraineurs with undiagnosed symptoms of GERD/
heartburn or those without GERD/heartburn. Migraineurs
with diagnosed heartburn reported a greater frequency of
migraine attacks per month (P = 0.05), more severe
migraines (P = 0.03), and having tension or chronic daily
headaches (P = 0.04 and \0.01, respectively) more often
than either migraineurs with undiagnosed symptoms of
GERD/heartburn or those who were GERD/heartburn-free.
Migraineurs with diagnosed GERD were somewhat more
likely to have nausea at headache onset than the rest of the
sample (P = 0.06). Patients with undiagnosed GERD/
heartburn symptoms were significantly less likely to be
under the care of a neurologist or headache specialist for
their migraines compared to those with diagnosed GERD,
diagnosed heartburn, or GERD/heartburn-free individuals
(P \ 0.01). They were also marginally less likely to have
health insurance which covers prescription medications
when compared to either the diagnosed or disease-free
populations, but this finding was not significant (P = 0.08).
Upon further examination of GERD in migraineurs with
other primary headaches, it was found that GERD diag-
nosis was more prevalent among patients with sinus
headache or tension-type headache. Of the 1,832 study
participants, 802 (43.7%) reported also having sinus
headache.
In total, 27.2% (n = 218) of those with sinus headache
reported GERD diagnosis compared to 20.1% of those
without sinus headache (n = 143; P = 0.005). Similarly,
936 migraineurs (51.1%) had co-prevalent tension-type
headache. Of them, 26.5% (n = 248) reported being
diagnosed with GERD in contrast to 19.5% of migraineurs
without tension-type headache (n = 113; P = 0.005).
Distribution of first migraine medication used by the
1,779 (97.1%) respondents who reported taking any med-
ication for their last migraine attack is shown in Table 2.
The majority of migraineurs from each sub-population
used a triptan as their first migraine medication (68.9% of
total). Migraineurs with diagnosed heartburn or diagnosed
GERD reported significantly more opioid and other pre-
scription medication use (P \ 0.01) compared to the rest of
the sample, while symptomatic but undiagnosed GERD/
heartburn migraineurs took significantly more aspirin-
containing drugs than did the diagnosed groups (P \ 0.01).
This relationship remained significant after adjustment for
all pair-wise comparisons.
OTC NSAIDs and aspirin-containing medications were
used more commonly than their prescription counterparts
across all migraine sub-populations (Table 2). There was
1.59 more frequent use of OTC versus prescription aspi-
rin-containing preparations among those with diagnosed
GERD (4.1 vs. 2.8%). OTC aspirin-containing use was
5.29 more common than prescription product use among
those with undiagnosed symptoms of GERD or heartburn
(11.0 vs. 2.1%). The OTC to prescription ratio for NSAID
use ranged from 1.6 to 2.1 greater OTC use across the four
migraine sub-populations.
Upon combining prescription and OTC preparations of
NSAIDs (and aspirins), significantly more migraineurs
with undiagnosed symptoms of GERD or heartburn
(17.8%) chose an NSAID/aspirin product as their first-line
J Headache Pain (2009) 10:35–43 37
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migraine medication compared to those with physician-
diagnosed GERD (10.0%), physician-diagnosed heartburn
(10.1%), or those who were GERD/heartburn free (11.8%;
P \ 0.01).
Discussion
In this cross-sectional study, the self-reported prevalence of
physician-diagnosed GERD among migraineurs was
22.0%, and the prevalence of diagnosed heartburn was
11.6%. Nearly half (49.4%) of the total migraine sample
reported being diagnosed with GERD or heartburn or
experiencing symptoms of these conditions within the past
year. The rates found in this study appear similar to esti-
mates within the general US population, which
approximate 20% for GERD [18] and up to 44% for
occasional heartburn symptoms [19]. Migraineurs with
comorbid tension-type or sinus headache were significantly
more likely to report being diagnosed with GERD than
migraineurs who did not report having additional head-
aches, a finding cited by previous research [10, 20].
An increased prevalence of gastroesophageal reflux
among migraine sufferers is supported by a report by
Featherstone [11] and is similar to the more recent findings
reported by Aamodt and colleagues [10], who found a
42.6% prevalence of reflux symptoms among Norwegian
migraineurs, an association which strengthened as the
amount of reflux symptoms increased. A small observa-
tional study in Italy [21] aimed to discover the rationale for
this apparent association, and found that migraineurs with
functional dyspepsia could be characterized by their
hypersensitivity to gastric distention and a lower discom-
fort threshold after meals when compared to both
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Fig. 1 Migraine sample
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dyspeptics without migraine and healthy volunteers. Fur-
thermore, clinical case studies have concluded that gastric
reflux disorders can trigger migraine headache originating
from specific locations [22].
The mechanism by which GERD and reflux symptoms
are increased among migraineurs is not clear, but is plau-
sibly related to the common etiology of both disorders.
Autonomic nervous system (ANS) dysfunction has been
shown to play a role in the pathogenesis of both reflux
disorders and migraine attacks [23, 24], which may explain
the overlap in GERD and migraine symptomatology.
Pathophysiologically, abnormal visceral mechanosensory
and vagal function has been found to play a role in dys-
peptic patients, and similarly, disturbances in visceral
nerves have been implicated in migraine [25, 26]. Neuro-
peptides such as the calcitonin gene-related peptide
(CGRP) have also played an important role in this asso-
ciation. CGRP is a neurotransmitter which helps to regulate
receptive relaxations in the stomach and gastrointestinal
tract, and studies find it is increased during migraine attack
[27]. It has been hypothesized that disorders of the reser-
voir functions mediated by CGRP may result in symptoms
of functional dyspepsia [28].
This study also observed that migraineurs with diag-
nosed GERD or heartburn conditions reported a slightly
higher incidence of nausea than their counterparts without
these conditions, an association which has been docu-
mented by the literature [10, 11]. In a clinic-based sample
of Italian patients referred for endoscopy, increased prev-
alence of migraine was reported in dysmotility-like (e.g.,
gastroparesis), but not reflux-like, dyspeptic patients [29].
Nonetheless, other studies have found that delayed gastric
emptying or gastroparesis itself plays a significant role in
the evolution of GERD [30]. It is estimated that gastro-
paresis is present in 15% of GERD patients, although
underdiagnosed. Research has confirmed that gastric statis
is present among migraineurs both during and outside of
migraine attacks [31]; which is suggestive of underlying




heartburn n = 212
Symptoms of GERD or
heartburn n = 290
No GERD or heartburn
symptoms n = 927
P value
Demographic characteristics
Age, mean (SD) 43.9 (11.1)c 42.1 (11.8) 39.2 (11.5) 40.3 (11.8) 0.05
Female (%) 69.5c 67.0c 75.9 75.1 0.02
College graduate (%) 38.9 41.5 45.2 46.4
Prescription drug insurance
(%)
88.6 86.3 83.8 88.8 0.08
Migraine characteristics
Age at diagnosis, mean (SD) 28.3 (12.1) 26.7 (11.5) 27.2 (10.9) 26.7 (10.6)
General migraine severity (%)
Mild 1.7 1.4 2.8 3.5
Moderate 37.7 39.2 47.2 50.0
Severe 60.5c 59.4c 50.0 53.4 0.03
Attack frequency per
montha, mean (SD)
6.2 (6.3) 6.7 (6.7)b 5.1 (5.5) 5.7 (6.1) 0.05
Other primary headaches (%)
Tension 80.9 84.4b 79.7 76.5 0.04
Cluster 36.5 40.6 37.2 35.0
Chronic daily 40.0c 39.6c 31.0 30.1 0.001
Sinus 69.2 68.9 64.8 64.7
Symptoms at headache onset (%)
Nausea 63.0 58.5 60.3 55.5 0.06
Vomiting 13.2 10.7 11.0 12.2
Migraine provider type (%)
Neurologist/headache
specialist
25.6 22.2 16.5c 24.2 \0.01
a Non-normal distribution
b Differences between groups 2 and 3 or groups 2 and 4
c Differences between groups 1 and 3, 1and 4; and/or groups 2 and 3, 2 and 4
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gastroesophageal disorder as much as it is of migraine. A
recent population-based study found that both nausea and
reflux can occur concurrently among headache sufferers
with high symptom loads, despite the lack of common
etiology between the two symptoms [10]. Given the sub-
stantial overlap between dysmotility-like and reflux-like
dyspepsia among those who experience any dyspepsic
symptoms [32], we believe the findings of our study sup-
port, at the very least, an association between dyspepsic
symptoms and migraine among those who may suffer from
pre-existing gastroesophageal conditions.
Upon examining migraine medication used at last
attack, we found a relatively high frequency of NSAID or
opioid use among migraineurs, classes of drugs that are
both associated with upper as well as lower GI symptoms.
Approximately 10% of migraineurs with physician-diag-
nosed GERD and 17% of migraineurs with undiagnosed
GERD or heartburn symptoms reported taking an NSAID,
aspirin, or an aspirin-containing product as their first-line
abortive medication for their most recent migraine attack,
and the rate of collective NSAID use among migraineurs
with physician-diagnosed GERD was comparable to that of
migraineurs without GERD or heartburn symptoms. Upper
GI symptoms including heartburn, reflux and dyspepsia are
common complaints in both prescription and OTC NSAID
users [16, 33]. NSAIDs have been shown to approximately
double the risk of development of GERD [15, 34] and have
also been shown to have other toxic effects on the
esophagus. Case–control studies have found an association
between NSAID consumption and esophageal strictures,
and NSAIDs have been reported to cause pill-induced
esophagitis, especially when the drugs are absorbed with-
out water as they might be during a migraine attack [35].
As it is well-known, NSAIDs also increase the risk of
gastroduodenal ulceration, bleeding, and perforation, even
with OTC or low-dose formulations [36]. Given the high
healthcare resource utilization associated with NSAID/
aspirin complications, the relatively frequent use of
NSAIDs as acute therapy among migraineurs with physi-
cian-diagnosed GERD or heartburn symptoms generates
some cause for clinical concern. In this study, we found
that triptans were most commonly used; which, unlike
NSAIDs, are drugs specifically indicated for migraine
treatment. Triptans, on the other hand, are contraindicated
in patients with ischemic heart disease or uncontrolled
hypertension. Although triptans are generally considered
safe when used appropriately according to the approved
label [37], physicians should obtain completed medical
histories in addition to migraine symptoms and carefully
evaluate the benefit risk trade-off before prescribing either
triptans or NSAIDs.
This study had several limitations which deserve men-
tion. Primarily, the prevalence of physician-diagnosed
GERD, heartburn symptoms, migraine and other headaches
were made on the basis of a patient self-reporting diag-
noses received by their doctor. However, we have no
reason to suspect that migraineurs reported being diag-
nosed with GERD if they were not. Patient-reported data of
this kind has been found to be reliable, and for the most
part consistent, with physician reports [38, 39].
Due to the lack of control for potential confounding in
this study, predictors linked to both GERD and migraine—
Table 2 Distribution of first medication used, by migraine sub-populations (n = 1,779)













Triptans 66.7 66.2 66.9 71.1
NSAID and NSAID-containing 3.1 4.8 4.6 5.6
Prescription 1.0 1.5 1.8 1.8
OTC 2.1 3.4 2.9 3.8
Aspirin and aspirin-containing 6.9 5.3 13.2a 6.2 \0.01
Prescription 2.8 1.5 2.1 1.1
OTC 4.1 3.9 11.0 5.1
Total NSAID and aspirin-containing
medication
10.0 10.1 17.8a 11.8 0.001
Opioids 6.2c 7.7b 2.1 4.4 \0.01
Prescription (other) 15.0c 15.0b 11.0 10.8 \0.01
OTC (other) 2.1 1.0 2.1 1.8
a Differences in group 3
b Differences in group 2
c Differences in group 1
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such as anxiety, depression, smoking, alcohol intake,
analgesic use or obesity—cannot be ruled out as an
explanation for the rate of GERD/heartburn observed
among this sample of migraineurs. But confounding seems
unlikely to account for the entire association, as the posi-
tive relationship observed between migraine and reflux
symptoms was only mildly attenuated after adjustment for
anxiety, depression and chronic medication use previously
[10]. Furthermore, another study which controlled for the
effects of smoking, gender, alcohol use and analgesic
intake in this association found no indication that the
higher prevalence of dyspepsia among migraineurs was
induced or modified by analgesic intake [26].
Given the cross-sectional nature this study and the
absence of a control group, the secondary data analysis
employed here could not establish a causal relationship
between migraine and GERD/heartburn in either direction.
We also recognize that the online survey format may have
biased our sample of migraineurs against those who are
older, of a lower SES level, or who do not have regular
internet access.
Because medication data was only available for the last
migraine attack experienced in this cross-sectional sample,
we were unable to show the effects of chronic NSAID use
by patients with GERD/heartburn; or the degree to which
NSAIDs used for migraine headache either causally con-
tribute to or worsen GERD over time. However, because
only the first migraine medication taken following a
migraine attack was recorded, our study likely significantly
underestimates the cumulative use of NSAIDs, aspirin, and
aspirin-containing medications during any given migraine
attack. Ng-Mak and colleagues recently found that in
addition to the 11% of migraineurs who treated their most
recent attack exclusively with an NSAID, triptan/NSAID
co-therapy and using an NSAID as rescue medication were
common practices when both classes of medication were
available to patients [14]. It was also shown that for the
patients with migraine-associated nausea, triptan/NSAID
therapy was seemingly less effective than triptan mono-
therapy in relieving nausea. Our study found a similar rate
of first-line NSAID use for acute migraine therapy for both
patients with physician diagnosed GERD or heartburn
(10.1%) and for those who were GERD/heartburn-free
(11.8%).
In addition to the apparent co-prevalence GERD or
heartburn among migraineurs and their fairly frequent use
of NSAIDs for migraine attacks, several other findings are
apparent from these results. We found that the most com-
monly used NSAID for the acute treatment of migraine was
an aspirin or aspirin-containing product. The broad avail-
ability of OTC aspirin products makes them popular
treatment choices for migraine as well as tension and other
headache types. Low-dose aspirin is also regularly used
among the general population for the prevention of stroke
and cardio-vascular events [40]. However, it is unlikely
that we included preventative aspirin use in our medication
type analysis, as aspirins taken for this purpose are gen-
erally taken at too low a dosage strength to be used as a
first-line acute migraine treatment.
While the majority of our sample population was diag-
nosed with GERD (n = 403) as opposed to diagnosed with
heartburn (n = 212), diagnosed heartburn accounted for
part of the significant differences seen with regard to
migraine characteristics and medication use among the
diagnosed population. Diagnosed heartburn was associated
with greater migraine severity, increased the presence of
both tension and chronic daily headaches and slightly more
opioid medication use among the combined diagnosed
population. While the absolute overlap of these highly
similar disorders is difficult to accurately assess, we found
that 72% of the diagnosed GERD population reported to
have heartburn symptoms, and 68% reported being co-
diagnosed with heartburn. Given the high rate of overlap
between symptomatic or ‘diagnosed’ GERD and heartburn,
the true rate of GERD disorder is likely underestimated in
this migraine sample.
A substantial proportion of those who reported undiag-
nosed GERD or heartburn symptoms used OTC NSAID or
aspirin regimens for first-line treatment of their migraine
attack; moreover, NSAID use was apparent in this group
than in the GERD or heartburn-free population. The
undiagnosed population was also significantly less likely to
see a headache specialist for their migraine symptoms than
were any of the other groups, and also marginally less
likely to have prescription drug insurance. We would
expect that these structural barriers increase their reliance
on OTC aspirin products. However, reliance on OTC
products may also be partially explained by the undiag-
nosed patient’s perception of his/her own illness severity
and their underlying belief that OTC medications are
effective in treating existing symptoms. Studies have found
that a high proportion of individuals with GERD perceive
their symptoms to be due to a trivial condition, and recently
research has found that a large majority (close to 78%) of
patients with undiagnosed GERD symptoms relied on OTC
medications to alleviate their symptoms [41]. This strong
reliance on OTC medications may make undiagnosed
GERD sufferers less likely to see a healthcare provider and
obtain a diagnosis for their symptoms to begin with.
While NSAIDs can be efficacious as acute migraine
therapy, medications containing this class of drugs may not
be appropriate for all patients. The common finding of
GERD among migraineurs coupled with their relatively
frequent use of NSAIDs should encourage physicians who
treat migraine to specifically inquire about the presence of
upper GI symptoms in patients. Approximately two-thirds
J Headache Pain (2009) 10:35–43 41
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of the NSAID, aspirin and aspirin-containing products
reported in this study were OTC, so physicians may be
unaware of the use of these medications during a migraine
attack; particularly, since the majority of OTC medication
use, unlike triptan or other prescription analgesic use, goes
unreported. Some GI patients medicate with OTC NSAIDs
for pain, and take additional OTC GI medications for GI
side effects [16] which may increase their risk of drug-
related interactions, unknown to the clinician. Because
migraineurs may vary their medication regimen from one
attack to the next [42], the need for increased physician–
patient communication regarding medication usage and the
risks and benefits of various migraine and heartburn-alle-
viating therapies may be critical for successsful migraine
management. Discussing the functional disability and
symptoms associated with migraine during initial consul-
tation has also been found to have a powerful impact on
physicians’ perception of illness severity as well as on their
choice of subsequent treatments for the patient [43].
To our knowledge, this is the first observational study
that estimates the co-prevalence of suspected GERD or
heartburn among migraine patients and documents their
use of anti-migraine medication during acute migraine
attack. The presence of GERD and heartburn symptoms
among migraineurs, coupled with their relatively frequent
use of NSAIDs, should encourage physicians to inquire
about the use of OTC analgesics among this population
and use discretion prior to prescribing appropriate
treatment.
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